CD274 and small cell lung carcinoma: Our discovery cohort was derived from a prospective clinical trial of 20 previously treated patients with SCLC who received durvalumab, an anti-PD-L1 antibody administered every 4 weeks and olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered twice daily15 (Fig. 1a).